Nuvation Bio Stock Surges on Early FDA Label Approval for Cancer Drug IBTROZI

Shares of Nuvation Bio (NUVB) surged 5.2% to $6.08 in morning trading after the U.S. Food and Drug Administration (FDA) granted an early approval for an updated label on its lead lung cancer drug, IBTROZI (taletrectinib), significantly strengthening the therapy's long-term efficacy data.

FDA Grants Early Label Update

The FDA's decision came four months ahead of the originally scheduled Prescription Drug User Fee Act (PDUFA) date. The approval incorporates updated clinical trial data with a median follow-up of approximately 51 months, according to Investing.com.

This new label adds 14 months of additional durability evidence for IBTROZI, a ROS1 inhibitor for non-small cell lung cancer. Crucially, it establishes a median duration of response of 49.7 months in tyrosine kinase inhibitor (TKI)-naïve patients, a key metric for demonstrating the drug's long-term effectiveness.

Ad

Analyst Confidence and Market Reaction

Adding to the positive momentum, Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and a $10.00 price target for Nuvation Bio. A note from the analyst highlighted IBTROZI's competitive advantage in the ROS1 inhibitor market.

Citizens characterized IBTROZI as having a roughly two-year head start over rival drugs from Nuvalent and GlaxoSmithKline, whose clinical data was described as more immature. The company-specific catalysts were amplified by a constructive market backdrop, with the S&P 500 and Nasdaq Composite both trading higher, providing a supportive environment for biotech stocks.